Drug Name: Loqtorzi
Active Ingredient: toripalimab-tpzi
Indication: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies
Approval Date: 10/27/2023
Company: Coherus BioSciences, Inc
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf